ethambutol

Brand: Myambutol

Prototype Drug
Drug Class: antimycobacterial agent
Drug Family: antibiotic
Subclass: arabinosyltransferase inhibitor
Organ Systems: infectious-disease

Mechanism of Action

Inhibits arabinosyltransferases involved in arabinan biosynthesis, a critical component of mycobacterial cell wall arabinogalactan and lipoarabinomannan; bacteriostatic; primarily used in TB regimens to prevent resistance emergence.

arabinosyltransferases (EmbA, EmbB, EmbC)

Indications

  • active tuberculosis (part of standard 4-drug initial regimen: RIPE)
  • MAC infections (in combination)

Contraindications

  • ethambutol hypersensitivity
  • optic neuritis (relative)
  • children too young to reliably monitor visual acuity

Adverse Effects

Common

  • GI upset
  • headache

Serious

  • optic neuritis (dose- and duration-dependent; reversible if caught early)
  • color vision loss (red-green discrimination)
  • peripheral neuropathy (less common)
  • hyperuricemia

Pharmacokinetics (ADME)

Absorption 75–80% oral bioavailability; unaffected by food
Distribution widely distributed; 50% enters red blood cells; poor CSF penetration (unless inflamed)
Metabolism hepatic partial oxidation
Excretion renal (50% unchanged); dose adjustment required in renal impairment
Half-life 3–4 hours
Onset 2–4 hours
Peak 2–4 hours
Duration 24 hours
Protein Binding 20–30%
Vd moderate

Drug Interactions

Drug / Agent Mechanism Severity
aluminum-containing antacids reduce ethambutol absorption; separate by 4 hours moderate

Nursing Considerations

  1. Baseline visual acuity testing (Snellen chart) and color vision testing (Ishihara plates) are mandatory before starting therapy and should be repeated monthly during therapy.
  2. Instruct patients to immediately report any change in vision, blurred vision, color vision disturbance, or eye pain — early discontinuation of ethambutol is essential to prevent permanent optic nerve damage.
  3. Reduce dose in renal impairment; monitor BUN and creatinine — ethambutol accumulates in kidney disease.
  4. Ethambutol is the 'E' in the standard RIPE regimen (Rifampin, Isoniazid, Pyrazinamide, Ethambutol); it can typically be discontinued once drug susceptibility results are confirmed.

Clinical Pearls

  • Optic neuritis from ethambutol is dose-dependent and usually reversible if the drug is stopped promptly; irreversible vision loss can occur with continued use, making visual monitoring mandatory.
  • Color vision loss (specifically red-green discrimination) often precedes visual acuity changes, making color vision testing a sensitive early monitoring tool.

Safety Profile

Pregnancy generally-safe
Lactation use-with-caution
Renal Adjustment Required
Hepatic Adjustment Not required
TDM Not required

Concordance Terms

Cross-referenced clinical concepts — click any term to see all content where it appears.